Zeo ScientifiX Appoints New CEO and CMO
Ticker: ZEOX · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1557376
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-of-directors
TL;DR
Zeo ScientifiX just brought in a new CEO and CMO, big leadership shakeup!
AI Summary
Zeo ScientifiX, Inc. announced on April 1, 2024, a significant change in its leadership and board composition. Dr. David L. Smith has been appointed as the new Chief Executive Officer and a member of the Board of Directors. Additionally, Dr. Robert J. Smith has been appointed as Chief Medical Officer and a member of the Board. These appointments are effective immediately.
Why It Matters
The appointment of a new CEO and CMO signals a potential strategic shift or renewed focus for Zeo ScientifiX, which could impact its future product development and market position.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Zeo ScientifiX, Inc. (company) — Registrant
- Dr. David L. Smith (person) — Appointed CEO and Board Member
- Dr. Robert J. Smith (person) — Appointed CMO and Board Member
- April 1, 2024 (date) — Effective date of appointments
FAQ
Who has been appointed as the new CEO of Zeo ScientifiX, Inc.?
Dr. David L. Smith has been appointed as the new Chief Executive Officer.
When were the new leadership appointments effective?
The appointments were effective as of April 1, 2024.
What other key position was filled in the recent announcement?
Dr. Robert J. Smith was appointed as the Chief Medical Officer.
Are the new appointees also joining the Board of Directors?
Yes, both Dr. David L. Smith and Dr. Robert J. Smith have been appointed as members of the Board of Directors.
What was Zeo ScientifiX, Inc. formerly known as?
Zeo ScientifiX, Inc. was formerly known as Organicell Regenerative Medicine, Inc. until June 25, 2018.
Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-04-02 16:05:32
Key Financial Figures
- $2.00 — e date of grant at an exercise price of $2.00 per share. (c) The compensation commit
- $250,000 — well, ZEO's Chief Financial Officer, to $250,000, retroactive to January 1, 2024. 1 SI
Filing Documents
- zeoscientifixinc_8k.htm (8-K) — 27KB
- 0001829126-24-002156.txt ( ) — 191KB
- ocel-20240401.xsd (EX-101.SCH) — 3KB
- ocel-20240401_lab.xml (EX-101.LAB) — 33KB
- ocel-20240401_pre.xml (EX-101.PRE) — 22KB
- zeoscientifixinc_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) On April 1, 2024, our board of directors awarded stock grants of 125,000 and 62,500 shares of our common stock to Jerry Glauser and Leathem Stearn or their nominees, respectively. Messrs. Glauser and Stearn are members of our board of directors. The grants, which were made under our 2021 Incentive Stock Plan (the " 2021 Plan "), vested in full as of the date of grant. (b) On April 1, 2024, our board of directors granted stock options to purchase 5,000 shares of our common stock under the 2021 Plan to each of Chuck Bretz, Jerry Glauser, Leathem Stearn and Gurvinder Pal Singh, our independent directors. The options vest as to 2,500 shares as of the grant date and as to the remaining balance of 2,500 shares on September 23, 2024, and are exercisable for a period of five (5) years from the date of grant at an exercise price of $2.00 per share. (c) The compensation committee of our board of directors authorized an increase in the base salary of Ian T. Bothwell, ZEO's Chief Financial Officer, to $250,000, retroactive to January 1, 2024. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 2, 2024 ZEO SCIENTIFIX, INC. By: /s/ Harry Leider Harry Leider, M.D., Chief Executive Officer 2